What is SNYR's health score?

Synergy CHC Corp. (SNYR) has a TradeApes health score of 41 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is SNYR's estimated fair value?

Based on our 5-year discounted cash flow model, Synergy CHC Corp.'s estimated fair value is $7.89 per share, representing a 4135.0% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is SNYR undervalued or overvalued?

Our model currently rates SNYR as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

Create an account for unlimited access

Synergy CHC Corp. (SNYR)

Healthcare Undervalued low weak

$0.19

Updated: 2026-07-18

TradeApes Score

Financial Strength

15 Stressed

Operating Trend

60 Healthy

Relative Value

40 Weak

Capital Allocation

45 Mixed

Risk Management

50 Mixed

Est. Fair Value $7.89

DCF Upside +4135.0%

Sector Rank #3690 of 12113

Key Findings

+ Free cash flow positive — business generates real spendable cash

Unlock Full Report →

− Very high leverage — net debt/EBITDA above 5×

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.